Evidence map›Paper›PMID 33193866›Full record

ArticleAsian journal of pharmaceutical sciences2020

Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance.

Yinghuan Li, Xi Tan, Xuhan Liu, Lingyan Liu, Yan Fang, Rong Rao, Yuanyuan Ren, Xiangliang Yang, Wei Liu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 65 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yinghuan LiSchool of Pharmaceutical Sciences, Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Capital Medical University, Beijing 100069, China.
Xi TanCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
Xuhan LiuCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
Lingyan LiuSchool of Pharmaceutical Sciences, Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Capital Medical University, Beijing 100069, China.
Yan FangCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
Rong RaoCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
Yuanyuan RenCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
Xiangliang YangCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
Wei LiuCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
Huazhong University of Science and Technology · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple drug resistance (MDR) is a tough problem in developing hepatocellular carcinoma (HCC) therapy. Here, we developed TPGS-coated cationic liposomes with Bcl-2 siRNA corona to load doxorubicin (Dox)

Indexed as

Bcl-2LiposomesMultiple drug resistance (MDR)P-glycoprotein (P-gp)siRNA-coronaTPGS

Identifiers

PMID33193866
PMCPMC7610212
OpenAlexW2983780543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.